What Researchers Did
Researchers conducted a systematic review and meta-analysis of twelve publications (six randomized controlled trials and six comparative observational studies) to evaluate the efficacy of hyperbaric oxygen therapy (HBOT) for nonhealing diabetic lower limb ulcers.
What They Found
Pooled analysis revealed that hyperbaric oxygen therapy (HBOT) reduced the risk of major amputation by 60% (p = .29) in randomized controlled trials and 61% (p = .003) in observational studies compared to standard wound care. The relative risk of having an unhealed wound following HBOT was 0.54 (p = .10) based on RCT data and 0.24 (p < .0001) from observational data.
What This Means for Canadian Patients
For Canadian patients with nonhealing diabetic foot ulcers, hyperbaric oxygen therapy (HBOT) may offer a potential benefit in reducing the risk of major amputation and promoting wound healing. However, given the limited conclusive evidence, treatment decisions should be made in consultation with healthcare providers, considering individual patient circumstances and available local guidelines.
Canadian Relevance
This systematic review and meta-analysis was conducted by Canadian researchers, making its findings directly relevant to health technology assessment and clinical practice within the Canadian healthcare system.
Study Limitations
The study's primary limitation is the limited randomized controlled trial evidence, which prevents conclusive establishment of the benefits and harms of hyperbaric oxygen therapy for diabetic lower limb ulcers.